Search research articles
Contact Us
Filters
Showing results (1-10 of 25) with videos related to
Page
of 3
Sort By:
Journal of Pediatric Gastroenterology and Nutrition
|
February 28, 2013
Autoantibodies in hepatitis C: red flag or bystander effect?
Michele M Tana, Theo Heller
NAM Perspectives
|
November 2, 2023
Timely Treatment Translates: A Vision for Eradicating HCV
Christopher M Bositis, Michele M Tana
JAMA
|
November 10, 2025
Primary Biliary Cholangitis
Michele M Tana, Gideon M Hirschfield
Clinical Liver Disease
|
April 18, 2019
Hepatitis B virus treatment: Management of antiviral drug resistance
Michele M Tana, Marc G Ghany
Lancet (London, England)
|
December 14, 2012
Scar undone: long-term therapy of hepatitis B
Michele M Tana, Jay H Hoofnagle
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
July 12, 2017
Diagnosing Liver Fibrosis and Cirrhosis: Serum, Imaging, or Tissue?
Michele M Tana, Andrew J Muir
JAMA
|
March 18, 2026
Primary Biliary Cholangitis and Prognostic Models-Reply
Michele M Tana, Gideon M Hirschfield
Clinical Liver Disease
|
February 2, 2022
Thinking Ahead: Advance Care Planning for Patients With Cirrhosis
Lisa X Deng, Michele M Tana, Jennifer C Lai
Hepatology (Baltimore, Md.)
|
May 31, 2021
We Are Not Immune: Racial and Ethnic Disparities in Autoimmune Liver Diseases
Brian T Lee, Michele M Tana, Jeffrey A Kahn, et al.
Hepatology (Baltimore, Md.)
|
August 29, 2021
Outcomes of pregnancy in autoimmune hepatitis: A population-based study
Connie W Wang, Joshua Grab, Michele M Tana, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 25) with videos related to
Sort By:
Page
of 3
Journal of Pediatric Gastroenterology and Nutrition
|
February 28, 2013
Autoantibodies in hepatitis C: red flag or bystander effect?
Michele M Tana, Theo Heller
NAM Perspectives
|
November 2, 2023
Timely Treatment Translates: A Vision for Eradicating HCV
Christopher M Bositis, Michele M Tana
JAMA
|
November 10, 2025
Primary Biliary Cholangitis
Michele M Tana, Gideon M Hirschfield
Clinical Liver Disease
|
April 18, 2019
Hepatitis B virus treatment: Management of antiviral drug resistance
Michele M Tana, Marc G Ghany
Lancet (London, England)
|
December 14, 2012
Scar undone: long-term therapy of hepatitis B
Michele M Tana, Jay H Hoofnagle
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
July 12, 2017
Diagnosing Liver Fibrosis and Cirrhosis: Serum, Imaging, or Tissue?
Michele M Tana, Andrew J Muir
JAMA
|
March 18, 2026
Primary Biliary Cholangitis and Prognostic Models-Reply
Michele M Tana, Gideon M Hirschfield
Clinical Liver Disease
|
February 2, 2022
Thinking Ahead: Advance Care Planning for Patients With Cirrhosis
Lisa X Deng, Michele M Tana, Jennifer C Lai
Hepatology (Baltimore, Md.)
|
May 31, 2021
We Are Not Immune: Racial and Ethnic Disparities in Autoimmune Liver Diseases
Brian T Lee, Michele M Tana, Jeffrey A Kahn, et al.
Hepatology (Baltimore, Md.)
|
August 29, 2021
Outcomes of pregnancy in autoimmune hepatitis: A population-based study
Connie W Wang, Joshua Grab, Michele M Tana, et al.
Page
of 3